Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Transcode Therapeutics Inc
(NQ:
RNAZ
)
1.790
+0.400 (+28.78%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Transcode Therapeutics Inc
< Previous
1
2
3
Next >
TransCode Therapeutics Reports Second Quarter 2023 Results; Provides Business Update
August 14, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces Positive Results in Non-human Primates with its Lead Therapeutic Candidate, TTX-MC138
July 31, 2023
Further Supporting TTX-MC138 Application in Metastatic Cancer
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Stonegate Healthcare Partners Announces Publishing of a Thematic Report - The RNA Revolution: Unleashing the Therapeutic Potential of RNAi
July 13, 2023
Dallas, Texas--(Newsfile Corp. - July 13, 2023) - Stonegate Healthcare Partners (SHP), a healthcare strategy consulting firm, is pleased to...
Via
Newsfile
TransCode Therapeutics CEO Letter to Shareholders
July 05, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces Publication of New Data Supporting the Use of TTX-MC138 for the Treatment of Metastatic Breast Cancer
June 22, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces Closing of $7 Million Public Offering
June 09, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces Pricing of $7 Million Public Offering
June 06, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Glioblastoma
June 06, 2023
Study provides support for further evaluation of TransCode’s lead therapeutic candidate, TTX-MC138, in clinical trials
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces 1-for-20 Reverse Stock Split
May 22, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial
April 27, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces Strategic Expansion of its Product Portfolio
April 26, 2023
Submits Provisional Patent Application entitled “Nanoparticles Comprising Payloads and Their In Vivo Delivery.”
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces Equity Investment from White Lion Capital to Help Fund Development of TTX-MC138 for Treatment of Glioblastomas
April 14, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics to present at AACR Annual Meeting 2023
April 06, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Receives Notice of Award from National Institutes of Health (NIH) for Third Year of Grant to Support Clinical Evaluation of TTX-MC138
April 05, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces Termination of Previously Announced Sale of Series A Preferred Stock
April 04, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces Agreement with Triton Funds for Sale of Series A Convertible Preferred Stock
April 03, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Reports 2022 Results; Provides Business Update
March 31, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces Orphan Drug Designation Status for TTX-MC138 for Treatment of Pancreatic Cancer
February 28, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics and BRAIN Biotech join forces to develop a CRISPR-derived technology platform for cancer treatment
February 22, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces Closing of $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
February 17, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
February 16, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma
January 31, 2023
Study provides additional support for further advancement of TTX-RIGA
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces FDA Authorization to Proceed with First-In-Human Clinical Trial
December 29, 2022
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Biotechs Race for New Treatments as Breast Cancer Therapeutics Market Could Reach $15 Billion by 2028
December 08, 2022
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:GILD),(NYSE:BMY),(NASDAQ:RXDS),(NASDAQ:RNAZ) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
COVID-19
TransCode Therapeutics Announces Withdrawal of Registration Statement
December 06, 2022
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors
November 30, 2022
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Reports Third Quarter 2022 Results; Provides Business Update
November 14, 2022
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer
November 10, 2022
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:MACK),(NASDAQ:NRBO),(NYSE:MRK),(NASDAQ:RNAZ), EQNX::TICKER_END
Via
FinancialNewsMedia
TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma
November 09, 2022
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics to Present at Sidoti Virtual Investor Conference
November 07, 2022
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.